When: Two-close breakout-retest above $70.10 resistance with volume >12M

Then: Add second half; validates accumulation thesis and invalidates distribution thesis

HOLD

• Stop placement at 66.60 is 4.4% below entry but target one at 72 is only 3.6% above entry, yielding approximately 0.8-to-1 reward-to-risk ratio, not the claimed 2-to-3.5
• FDA lawsuit is a defensive action by management who have exhausted regulatory remedies, not a bullish signal; unfavorable resolution or damaging discovery documents represent unpriced left-tail risk
• 6.4% dividend yield compensates for real risks: 93% GAAP payout ratio, 4-6% annual structural cigarette volume decline, and accelerating mix deterioration from Basic brand and discount segment growth
• Polymarket M&A probability contracts at 39-43% are illiquid prediction markets with thin volume subject to violent moves on small order flow, not institutional conviction signals
• 14.3 million share volume spike at resistance with stagnant close represents text-book institutional distribution behavior, not noise; aggressive analyst's logic about dismissing small candles is confirmation bias
• 5% ten-year and defensive rotation provides macro cushion but does not eliminate stock-specific risks including FDA litigation, payout ratio scrutiny, and structural decline

→ vs aggressive: Aggressive analyst's 2-to-3.5 reward-to-risk ratio is mathematically flawed; accounting for realistic stop-out probability in a binary regulatory exposure yields approximately 0.8-to-1

→ vs aggressive: FDA lawsuit framing as bullish catalyst is backward; Altria's litigation represents exhausted regulatory remedies and defensive positioning, not confident bullish action

→ vs aggressive: Calling 6.4% yield 'getting paid to wait' ignores that this is deferred compensation for regulatory and structural risk, not free money

→ vs aggressive: Polymarket probability contracts at 39-43% represent prediction market noise, not smart money signaling; M&A would dilute FCF and signal cigarette franchise decay

→ vs aggressive: Dismissing 14.3 million share volume day as 'noise' due to small candle is confirmation bias; volume precedes price and institutional selling into strength is text-book distribution

→ vs aggressive: Constructive macro backdrop does not eliminate stock-specific risk; defensive yield helmet does not prevent falling knife dynamics from headline risk

HOLD with conditional buy framework: existing positions held, new capital not deployed at current levels; two tiered entry triggers proposed instead

• R/R recalculation: entry at 68.55, stop at 66.60, target 72 yields 1.77:1; target 73.60 yields 2.6:1; the 3.5:1 figure requires no slippage or whipsaw in a name with 1.46 ATR and binary regulatory risk
• Dividend income only benefits existing holders; 1.6% quarterly yield does not offset regulatory risk for new capital buying into resistance at 69.52
• Volume analysis: 14.3 million share day with 0.26% close at round-number 70 is consistent with institutional distribution, not just bullish digestion; both bullish and bearish interpretations are valid
• FDA lawsuit does not eliminate fundamental floor: 6.4% dividend yield covered by 9 billion in FCF, 1.4x net debt to EBITDA, and 200 SMA at 64.74 provides structural support
• Polymarket M&A probability (40% across five targets) should not be dismissed as noise; even at a 15-20% haircut, it represents meaningful asymmetric call option value
• Macro tailwind: 5% ten-year and Fed on hold is the core investment thesis for MO as a yield vehicle; removing it leaves only slow-decline tobacco risk
• Trigger A: buy on confirmed daily close above 70.10 with volume above 12 million shares; stop at 68.50; targets 72.00 and 73.60; size at half normal weight
• Trigger B: buy on retracement to 67.00-67.50 zone (September 8-9 swing lows); stop at 65.48; targets 72.00 for approximately 2:1 R/R
• Existing holders: HOLD stands; dividend is being collected and technical structure remains intact; no reason to trim into consolidation or healthy pullback
• Position sizing refinement: no more than 75% of target weight until FDA lawsuit discovery phase produces procedural outcome

→ vs aggressive: R/R math is overstated at 2-3.5:1; actual 1.77:1 to 2.6:1 with ATR of 1.46 and binary catalyst; distribution at 14.3M share day is a valid bearish interpretation

→ vs conservative: Fundamental floor exists regardless of court case; 6.4% yield, 9B FCF, 1.4x leverage, and 200 SMA at 64.74 bound downside; Polymarket 40% M&A probability should not be priced at zero; macro backdrop is not just a cushion but the entire yield thesis